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Abstract
Background: There continues to be debate about what constitutes a pragmatic trial and how it is distinguished
from more traditional explanatory trials. The NIH Pragmatic Trials Collaborative Project, which includes five trials and
a coordinating unit, has adopted the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS-2) instrument.
The purpose of the study was to collect PRECIS-2 ratings at two points in time to assess whether the tool was
sensitive to change in trial design, and to explore with investigators the rationale for rating shifts.
Methods: A mixed-methods design included sequential collection and analysis of quantitative data (PRECIS-2
ratings) and qualitative data. Ratings were collected at two annual, in-person project meetings, and subsequent
interviews conducted with investigators were recorded, transcribed, and coded using NVivo 11 Pro for Windows.
Rating shifts were coded as either (1) actual change (reflects a change in procedure or protocol), (2) primarily a
rating shift reflecting rater variability, or (3) themes that reflect important concepts about the tool and/or pragmatic
trial design.
Results: Based on PRECIS-2 ratings, each trial was highly pragmatic at the planning phase and remained so 1 year
later in the early phases of trial implementation. Over half of the 45 paired ratings for the nine PRECIS-2 domains
indicated a rating change from Time 1 to Time 2 (N = 24, 53%). Of the 24 rating changes, only three represented a
true change in the design of the trial. Analysis of rationales for rating shifts identified critical themes associated with
the tool or pragmatic trial design more generally. Each trial contributed one or more relevant comments, with
Eligibility, Flexibility of Adherence, and Follow-up each accounting for more than one.
Conclusions: PRECIS-2 has proved useful for “framing the conversation” about trial design among members of
the Pragmatic Trials Collaborative Project. Our findings suggest that design elements assessed by the PRECIS-2
tool may represent mostly stable decisions. Overall, there has been a positive response to using PRECIS-2 to
guide conversations around trial design, and the project’s focus on the use of the tool by this group of early
adopters has provided valuable feedback to inform future trainings on the tool.
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Background
The need for trials with greater applicability or external
validity has been highlighted by many [1–3], and is the
most frequent criticism by clinicians of randomized con-
trol trials (RCTs), systematic reviews, and guidelines [1].
It has been over 50 years since Schwartz and Lellouch
introduced the concept of pragmatic trials, which are
performed under more typical conditions with the
intention of providing practical results more applicable
to clinical practice and decision-making [4, 5]. The de-
sign of a pragmatic or effectiveness trial should include a
research question relevant to the general population of
people with the targeted condition; test interventions in
settings close to usual care; and provide more applicable
information vital to enabling patients, clinicians, and
policymakers to make informed decisions about health-
care. While explanatory (efficacy) trials conducted under
ideal conditions play an important role in scientific dis-
covery, healthcare interventions are seldom delivered or
monitored under circumstances similar to more con-
strained trials [6, 7], underscoring the need for prag-
matic trials as well.
Despite an exponential rise in the number of trials de-
scribed as pragmatic, and the creation in 2014 of a new
Medical Subject Heading term “pragmatic clinical trial”
by the National Library of Medicine (NLM) at the Na-
tional Institutes of Health (NIH) [8], there continues to
be debate about what constitutes a pragmatic trial, how
it is distinguished from more traditional explanatory tri-
als, and strategies or tools for designing and describing
pragmatic trial characteristics. As there is seldom a
purely explanatory or entirely pragmatic trial, there is
value in exploring the distinctions underlying this con-
tinuum of design decisions, as well as implications of
these decisions for the conduct of research (e.g., re-
sources, feasibility, organizational or system buy-in,
stakeholder engagement, technological requirements).
The Pragmatic-Explanatory Continuum Indicator Sum-
mary (PRECIS-2) instrument helps researchers design
trials that focus on the end user(s) of trial results and
the match between trial design and usual care [9].
PRECIS-2 takes the innovative approach of translating
ratings on domains related to trial design to a readily
understood wheel format that communicates where the
trial design falls on the explanatory-pragmatic con-
tinuum. Moher et al.’s review on the value of biomedical
research also referenced PRECIS-2 as a tool to help re-
duce research waste by increasing efficiencies in trial de-
sign [10], consistent with the purpose of the tool to
assist in planning trials that more closely match the
goals of the study. PRECIS-2 was also used by Johnson
et al. [11] to indicate trial design decisions for the NIH
Health Care Systems Research Collaboratory, which sup-
ports pragmatic clinical trial demonstration projects and
seeks to create a sustainable infrastructure to improve
the design, conduct, and execution of clinical trials. Our
project presumes that a secondary benefit of an increase
in familiarity with and adoption of the tool is the build-
ing of a shared vocabulary for clinical investigators to
communicate about trial design decisions and the factors
that influence them. In a similar vein, for example, the
PRECIS-2 domains were the organizing framework to
describe strengths and limitations, and to consolidate
the pragmatic features of eight exemplar, large, simple
trials [12].
NIH Pragmatic Trials Collaborative Project
A new effort to implement and learn from a group of
pragmatic trials was initiated in 2014 in response to an
NIH Request for Applications (RFA) to fund low-cost,
pragmatic, patient-centered randomized controlled clin-
ical trials. As specified in the RFA, trials were required
to have a minimal, separate research infrastructure and
include randomization at the point of patient care, have
minimal eligibility criteria, and integrate data collection
into or obtained from routine clinical records or existing
electronic resources. Interventions were to be delivered
as part of routine usual care, with outcomes important
to patients and providers. As several NIH institutes were
participating in this initiative, variability in interventions
and outcomes between the trials was expected. The first
phase of the two-phase cooperative agreement funding
mechanism, which aims for early identification of trials at
risk and funds the UH3 4-year implementation phase con-
tingent on administrative review of milestone achieve-
ment, supported start-up activities including refinement
of existing resources, further development of study part-
nerships, conduct of feasibility studies, and finalization of
trial protocols. Five of six trials receiving UH2 funds dem-
onstrated trial feasibility and transitioned to the 4-year
UH3 trial phase; see Table 1.
A separate award established a coordinating unit to
support collaborative activities and monitor milestone
achievement. Awardees and NIH project officers partici-
pate in joint activities to gain a better understanding of
the struggles and successes of trial planning and imple-
mentation, explore the significance of stakeholder en-
gagement to trial success, and identify challenges to
meeting recruitment and retention goals.
Objectives
The purpose of this study was to collect PRECIS-2 rat-
ings at two points in time, assess whether the tool was
sensitive to change in design, and explore investigators’
experiences and impressions of the tool. In this paper,
we describe how the tool was introduced and used by
members of the Pragmatic Trials Collaborative Project,
and synthesize findings from discussions with the trial
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investigators to further clarify important distinctions
pertaining to the explanatory-pragmatic continuum.
The PRECIS-2 tool
The tool is designed to assess and document the position
of a trial within the pragmatic-explanatory continuum
[13–16]. PRECIS-2 requires investigators to consider nine
distinct domains in relation to the intended purpose of
the trial; these can be rated from “1” ideal setting (ex-
planatory) to “5” more real-world, usual care (pragmatic).
The domains covered include Eligibility Criteria, Re-
cruitment Path, Setting, Organization, Flexibility of
Delivery of Experimental Intervention, Flexibility of
Adherence of Experimental Intervention, Follow-up,
Primary Outcome, and Primary Analysis (see Table 2).
Evidence from the interactive PRECIS-2 website re-
source (https://www.precis-2.org/) [17] indicates that
the tool is being used by investigators across many
different contexts [18–25], and that wheel results are
included in study protocols [26, 27].
Table 2 Nine PRECIS-2 domains for assessing trial designing characteristicsa
Domain Assessment considerations
Eligibility To what extent are the participants in the trial similar to patients who would receive this intervention if it was part of usual care?
For example, score 5 for very pragmatic criteria essentially identical to those in usual care; score 1 for a very explanatory
approach with lots of exclusions (e.g., those who do not comply, respond to treatment, or are not at high risk for primary
outcome, are children or elderly), or uses many selection tests not used in usual care
Recruitment Path How much extra effort is made to recruit participants over and above what would be used in the usual care setting to
engage with patients?
For example, score 5 for very pragmatic recruitment through usual appointments or clinic; score 1 for a very explanatory
approach with targeted invitation letters, advertising in newspapers, radio plus incentives and other routes that would not
be used in usual care.
Setting How different are the settings of the trial from the usual care setting?
For example, score 5 for a very pragmatic choice using identical settings to usual care; score 1, for a very explanatory approach
with only a single center, or only specialized trial or academic centersb
Organization How different are the resources, provider expertise, and organization of care delivery in the intervention group of the trial
from those available in usual care?
For example, score 5 for a very pragmatic choice that uses identical organization to usual care; score 1 for a very
explanatory approach if the trial increases staff levels, gives additional training, require more than usual experience or
certification and increase resources
Flexibility in Delivery How different is the flexibility in how the intervention is delivered from the flexibility anticipated in usual care?
For example, score 5 for a very pragmatic choice with identical flexibility to usual care; score 1 for a very explanatory
approach if there is a strict protocol, monitoring and measures to improve compliance, with specific advice on allowed
co-interventions and complications
Flexibility in Adherence How different is the flexibility in how participants are monitored and encouraged to adhere to the intervention from the
flexibility anticipated in usual care?
For example, score 5 for a very pragmatic choice involving no more than usual encouragement to adhere to the intervention;
score 1 for a very explanatory approach that involves exclusion based on adherence, and measures to improve adherence if
found wanting. In some trials e.g., surgical trials where patients are being operated on or intensive care unit trials where patients
are being given intravenously administered drug therapy, this domain is not applicable as there is no compliance issue after
consent has been given, so this score should be left blank
Follow-up How different is the intensity of measurement and the follow-up of participants in the trial from the typical follow-up in
usual care?
For example, score 5 for a very pragmatic approach with no more than usual follow-up; score 1 for a very explanatory
approach with more frequent, longer visits, unscheduled visits triggered by primary outcome event or intervening event,
and more extensive data collection
Primary Outcome To what extent is the primary outcome of the trial directly relevant to participants?
For example, score 5 for a very pragmatic choice where the outcome is of obvious importance to participants; score 1 for a
very explanatory approach using a surrogate, physiological outcome, central adjudication or use assessment expertise that
is not available in usual care, or the outcome is measured at an earlier time than in usual care
Primary Analysis To what extent are all data included in the analysis of the primary outcome?
For example, score 5 for a very pragmatic approach using intention-to-treat with all available data; score 1 for a very
explanatory analysis that excludes ineligible post-randomization participants, includes only completers or those following
the treatment protocol
aPRECIS-2. 2016. https://www.precis-2.org/ [17]
bInstructions to rate Setting are derived from a systematic review done with physicians in Toronto on the hypertension trials. The new scheme addresses the
question of How different are the settings of the trial from the usual care setting?
5 = Trial is multi-center and all centers are typical of those for treating patients with hypertension in usual care
4 = Trial is multi-center but one or two of the centers are not usual care but specialized settings e.g., lead center university or specialized secondary care are
also centers
3 = Trial is multi-center but many of the centers appear not typical of usual care
2 = A single center which may be similar to usual care setting for treating patients with hypertension. Even if it is a primary care center
1 = A single center definitely specialized or academic center not typical of usual care setting for patients with hypertension
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Methods
Study participants
The five principal investigators (PIs) funded under this
initiative participated in the study. All members of the
project in attendance (which includes the coordinating
unit staff and nine NIH program staff officers) partici-
pated in discussions and training on the PRECIS-2 tool
and in development of the concept for this paper. The
PIs had the opportunity to provide feedback on an early
draft of the findings.
Our mixed-methods design structure can be described
as quantitative analysis preceding qualitative analysis
(quan→QUAL)—i.e., sequential collection and analysis
of quantitative data (PRECIS-2 ratings) and qualitative
methods, specifically follow-up interviews with PIs, with
emphasis on the qualitative data. The function of the
analysis was primarily expansion, whereby the qualitative
data were used to understand what shifts in PI ratings
reflected about the pragmatic trial domains [28, 29].
PRECIS-2 ratings were recorded on a worksheet and
collected at two annual, in-person project meetings.
After a presentation and brief training on the tool at the
first meeting shortly after funding awards for the plan-
ning phase were made (February 2015; Time 1), PIs
rated their trials as currently designed based on their
knowledge of the trial. Following a refresher session at
the second annual meeting shortly after trials were initi-
ated (April 2016; Time 2), PIs again rated the current
status of their trials on each domain, without reference
to Time 1 ratings or to any other documentation. Subse-
quently, a semistructured interview guide was developed
to frame the conduct of qualitative telephone interviews,
conducted with each PI by author PDL in summer 2016.
In addition to discussing domains with a change in rat-
ings, PIs were asked about their impressions of the tool
(Have you used the tool when designing other trials?;
Have you recommended the tool to colleagues or seen an
increase in use of the tool?; and Do you have any other
feedback regarding the tool?) and to provide ratings as
follows: How strongly do you agree with these two state-
ments, on a rating scale from 5 (strongly agree) to 1
(strongly disagree)? [16]; (1) PRECIS-2 would have been
useful in the design phase of the trial and (2) PRECIS-2
highlighted areas of trial design which are important for
your trial to achieve its goals.
A summary table of PI ratings was provided in ad-
vance of the call for reference during the discussion. For
each rating change, by domain, the interviewer noted
the direction of the change (more or less pragmatic),
and asked the PI what changed from Time 1 (T1) to
Time 2 (T2). If the revised rating truly reflected a modi-
fication to the trial, the PI provided a description and ra-
tionale. If there was no trial modification, the PI was
asked to explain the rating shift. The focus of the
discussion was on detecting trial design change and not
on the value or direction of the rating. Interviews were
recorded and transcribed and coded using NVivo ver-
sion 11 Pro for Windows, Baltimore, US licensed issued
from October 2016 through 2017. The documents were
initially coded by one team member (DM), who used
NVivo to extract each instance of PRECIS-2 rating shifts
and content to analyze the stated circumstances and ra-
tionale. The results of the initial coding and analysis
were reviewed and deliberated in depth with team
members (KL, RM, DM, PDL, LD) to agree on the
characterization of each instance. From this analysis,
four categories of rating changes were initially identified
which included two separate categories labeled “miscate-
gorization” and “misunderstanding.” However, when the
analysts independently coded the themes there was lack
of inter-coder reliability suggesting that these were indis-
tinct. The final analysis included: (1) actual change (re-
flects a change in procedure or protocol), (2) primarily a
rating shift reflecting rater variability (e.g., the PIs rating
changed but not due to a trial adaptation), and (3)
themes that reflect important concepts about the tool
and/or pragmatic trial design (further explored for add-
itional clarity regarding use of the tool).
Results
PRECIS-2 ratings
PI ratings at each time point (T1, T2) are presented in
Table 3 below. T1 ratings were used to generate a trial-
specific PRECIS-2 plot using the tool on the PRECIS-2
website (https://precis-2.org/) [17]; see Fig. 1 below.
When assessing whether the trials met the RFA re-
quirements that aligned with the PRECIS-2 domains
(specifically, Eligibility, Recruitment Path, Organization,
Flexibility of Intervention Delivery, Follow-up, and Pri-
mary Outcomes) we found that all but one was rated to-
ward pragmatic (ratings of 4 or 5) on five of six domains
(for the first rating T1 reflecting the UH2 planning
phase). Ratings lower than 4 were found for the Electro-
encephalograph Guidance of Anesthesia to Alleviate
Geriatric Syndromes (ENGAGES) trial [30] (Follow-up),
for the Pragmatic Trial of Behavioral Interventions for
Insomnia in Hypertensive Patients (HUSH) trial [31]
(Organization, Flexibility of Intervention Delivery,
Follow-up), for the Pragmatic Trial of Airway Manage-
ment in Out-of-Hospital Cardiac Arrest (PART) trial
[32] (Eligibility), and for the Prevention of Severe Acute
Respiratory Failure in Patients (PROOFCheck) trial [33]
(Organization). The five PIs completed paired ratings
(i.e., T1 to T2) for the nine PRECIS-2 domains) for a
total of 45 paired ratings. Those indicating a rating
change from T1 to T2 (N = 24, 53%) were the focus of
the qualitative data collection and analysis.
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Qualitative findings
Three broad categories of responses were identified. Of
the 24 rating changes, only three represented a true
change in the design of the trial. The remaining re-
sponses were evenly split between simple rating shifts
reflecting rater variability (N = 10), and those reflecting
important concepts about the tool or pragmatic trial de-
sign (N = 11).
Change in trial design
For the PART trial [32], loosening of eligibility cri-
teria over time resulted in a design shift toward prag-
matism. Initially, there were more exclusion criteria,
but the PI indicated that several criteria were re-
moved as of the second rating period (implementa-
tion). The final rating on the Eligibility domain was a
“5,” reflecting that trial participants were perceived to
be nearly identical to those likely to receive the inter-
vention under usual care conditions: “We did loosen
up one or two more additional criteria,” stated the
PART PI, “[5 is the correct rating because] we are in-
cluding as broad a selection of patients as possible
with very few exclusion criteria.”
The ENGAGES trial [30] experienced two design
changes in the more explanatory direction. The PI ex-
plained that they “discovered that we do actually need
more training [of the clinicians] than anticipated so
that’s why I think Organization is a bit more explanatory
than we had…anticipated originally.” Because additional
organizational resources to train the clinicians were
needed (beyond those available in usual care) the rating
on this domain shifted to a less pragmatic rating. The
need to increase monitoring of intervention delivery
contributed to a shift in rating for the Flexibility of
Intervention Delivery domain. As described by the PI, “I
changed [the rating] because the protocol is a little bit
more prescriptive than initially suggested. A [lower score]
is reasonable considering our experience now. I think that
a 4 is what we had anticipated and a 3 is closer to our
actual experience.”
Shift in rating
Examples of statements primarily reflecting rater vari-
ability included the following: (1) “I don’t think it’s be-
come less pragmatic [Recruitment Path]. I think I
probably overrated its pragmatism the first time,” and
Table 3 PRECIS-2 principal investigator (PI) ratings at trial planning (Time 1) and trial implementation (Time 2)
Actual change (N = 3, 13%)
Rating shift/rater variability (N = 10, 42%)
Thematic responses requiring clarification (N = 11, 46%)
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(2) “I’m not sure why I gave it a 4 the first time. I mean
it’s about as pragmatic as it gets [Setting].” In some cases
the shift was attributed to a new understanding of the
trial rather than a change in design. For example, with
regard to Setting, one investigator concluded that the
study sites are more representative and comparable to
usual care than was initially thought, and another real-
ized that intensity of Follow-up was less than anticipated
and did not involve additional patient visits.
Pragmatic trial themes
The remaining responses are the primary focus of the
analysis, as they illuminated important concepts relevant
to either the tool or to the design of pragmatic trials.
Each trial contributed one or more comments, which fell
within six of the nine domains, with Eligibility, Flexibility
of Adherence, and Follow-up each accounting for more
than one. Issues (by domain), the associated PI state-
ment, and clarification regarding the rationale for the
rating are presented in Table 4.
Reflections on the tool
Two of the PIs had used the original PRECIS (2009) [14]
tool to assess the design of their protocols. The other
three were unfamiliar with the tool (or its predecessor)
prior to the project; however, all agreed that PRECIS-2
would have been helpful at the design phase of their
trials (Table 5).
One of the PIs reported recently using the tool in a
grant application, and two others reported disseminating
it to other colleagues, “[I am] continuing to use it. And
we have recommended it to colleagues.” Another PI com-
mented that the tool would “be useful for myself and
others in designing future studies” stating “I really do
hope that some of my colleagues start to use it on a more
routine basis [to] report…just like clinical trials have to
include a CONSORT flow chart.” Other illustrative posi-
tive statements indicated that the tool was helpful as a
“good mental/academic exercise” and that “it does help
me conceptualize my argument about why my trial is
pragmatic.”
The respondents also reflected lingering confusion re-
garding the tool: “I think that even now some of them
[domains] are very obvious and intuitive…some of them
the ranges in the scores were very tight and some the
ranges were quite wide and I think that reflects some am-
biguity in the tool.” There were also several comments
pertaining to specific domains. For example, “…Eligibil-
ity and Recruitment are really…key…[to] how we design
trials…and its guided our thinking in terms of the effects
of different consent approaches, which are appropriate for
pragmatic trials.” An issue with the Follow-up domain
Fig. 1 PRECIS-2 principal investigator (PI) plots by study trial (trial planning phase – Time 1)
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was described thus: “We’d like to get long-term outcomes
data, but that would really change the budget require-
ments and the pragmatism considerably.”
Discussion
PRECIS-2 is a useful tool that increases transparency in
design decisions and which has proved useful for
Table 4 Thematic responses and clarification by domain (N = 11)
Domain (N) Interpretation and PI responses Domain clarification
Eligibility 1. Less pragmatic due to additional effort needed to identify
appropriate patients and to validate correct identification:
“It’s a little more work to figure out patients who are
chronically vented who are excluded…I just thought it was
going to be very, very easy and you don’t have to think about
it. But it turns out actually I have to have my staff validate it.”
(PI)
Eligibility refers to the extent to which the trial population
matches the population intended for the intervention. The
issue of effort to engage participants is more relevant to
Recruitment Path, which addresses whether effort to recruit
participants is greater than for patient engagement in usual
care
2. Less pragmatic due to a higher proportion of patients
excluded than originally anticipated: “Once we started
applying the criteria, we recognized…there are some people
who we’ve excluded and I think they’re for good reasons…
we haven’t changed the criteria, it’s just that as we’ve been
applying them, we realized that it excludes a larger
percentage of people perhaps than we thought.” (PI)
For the Eligibility domain one should consider the extent to
which trial participants are similar to those who would
receive the intervention if it were part of usual care (rather
than volume of participants excluded)
Setting 3. Setting is similar to usual care. “The setting is really the
identical setting to usual care. But I probably scored it a bit
down [at T1] it’s very representative of a usual setting.” (PI)
Setting receives a more explanatory score if there is only a
single center, or only a specialized trial or academic center.
Multi-center trials can be rated 3–5
Flexibility-Delivery 4. More pragmatic because clinician notification (re: eligibility)
was more automated than anticipated. “When we were in
the planning phase…not clear how we were going to notify
the [___]. It turns out the hospital itself had an outside
vendor trying to figure out actually how to link …that
[mechanism] is part of the hospital infrastructure now.” (PI)
Resource requirements are addressed under the Organization;
the issue of resources required to conduct the study is not
relevant to intervention delivery or adherence
Flexibility-Adherence 5. More pragmatic because notification (re: patient eligibility)
was more automated than anticipateda: “When we were in
the planning phase, [it wasn’t] clear to us exactly how we
were going to notify the ___ – ” (PI)
Resource requirements are addressed under the Organization
(see above). This domain should not have been rated as there
is no monitoring of patient adherence
6. More pragmatic because no participants are excluded due
to adherence: “We’re not excluding anybody based on
adherence, but we are encouraging adherence and are
providing feedback on adherence.” (PI)
This domain addresses how flexibly participants in the trial
are monitored and encouraged compared to usual care. This
domain is not applicable to 2 of the trials as there is no
compliance issue after consent has been given. The domain
should be left blank (unrated)
7. More pragmatic because the intervention is executed in
emergency care and adherence is minimal: “Our
intervention really is executed and then it’s done, so the
adherence of it is actually very minimal and the remainder of
care given thereafter is just standard of care.” (PI)
8. Less pragmatic because there is no usual care comparison:
“There’s no way to know what would happen in usual care
because the intervention’s never been tried in usual care. But I
would foresee if our results prove favorable that the
implementation in the real world would be identical to what
we’re testing.” (PI)
The issue of usual care comparison is relevant to Flexibility of
Intervention Delivery rather than Adherence
Follow-up 9. Less pragmatic as collection of follow-up requires more ef
fort than anticipated: “In clinical care, one would not
necessarily seek out follow-up on patients,…what made us
think that it was less pragmatic was the manner by which
you seek out that information.” (PI)
Does not apply to this domain, which is concerned only with
burden of follow-up on the participants, not whether the
follow-up data are routinely collected
10. Less pragmatic as collection of follow-up is less automatic
than anticipated: “I have to apply in a separate IRB to a
statistics department to get that long term follow-up. And
that requires linking of the patient’s data. So that’s just a
little less automatic…more work for me. For patients it’s the
same.” (PI)
This domain is concerned only with burden of follow-up on
the participants, not burden on research team or effort
needed to collect the follow-up data
Primary Analysis 11. Less pragmatic because the primary outcomes are not a
standard measure: “The analysis is a standard analysis one
would do for this type of a trial, but [not] a standard
comparison that one would make on a daily basis.” (PI)
Pragmatism of primary analysis is based only on the degree
to which all data are included in the analysis of the primary
outcome
aSame consideration was applied for both Flexibility of Delivery and Flexibility of Adherence
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“framing the conversation” about trial design among
members of the Pragmatic Trials Collaborative Project.
This concurs with experiences at the Pragmatic Clinical
Trials Unit in London where the PRECIS-2 tool
highlighted trial design decisions, which facilitated valu-
able discussion [16]. Based on PRECIS-2 ratings, each of
the five trials was highly pragmatic at the planning phase
and remained so 1 year later in the early phases of trial
implementation. Our approach to using the tool at dif-
ferent points in time to detect change suggests that the
design elements assessed by the PRECIS-2 tool may rep-
resent mostly stable decisions. Using this methodology,
we identified only two trials with any actual changes in
design.
Discussions with the PIs also helped to identify several
issues that are important to address as we refine the
conversation around the use of PRECIS-2, seek to im-
prove the tool, and advance our understanding of prag-
matic design decisions. The remainder of our discussion
draws on specific information from the trials to further
elaborate on these elements in relation to the domain
ratings.
Eligibility
This domain can have a range of ratings if there is un-
certainty about who would be treated in usual care for a
particular condition. It requires in-depth knowledge
about the research area and can be one of the most
common areas reducing external validity of results [6, 7].
A pragmatic trial would include anyone who would usu-
ally receive the intervention, and exclude those who
would not routinely get the treatment (regardless of the
number of people in this group):
 For example, in the PART trial [32] testing airway
management for resuscitation from out-of-hospital
cardiopulmonary arrest (OHCA) endotracheal
intubation (ETI) supraglottic airways (SGA),
participants included were all adults who needed
airway management following cardiac arrest.
Exclusions were vulnerable populations who had
“Do Not Resuscitate” orders, traumatic cardiac
arrest, and children, which are routine exclusions
and, therefore, very pragmatic. The only group that
would be treated in usual care that were excluded
were pregnant women and prisoners but these are
usual Institutional Review Board (IRB) exclusions as
protected groups.
Organization
There can be ambiguity in scoring the Organization do-
main as this includes knowledge of the current organization
including existing healthcare staff and resources. Adding
additional resources or infrastructure solely for the pur-
poses of research (i.e., not part of the intervention) moves
the rating more in the explanatory direction:
 For example, in the HUSH trial [31], cognitive
behavioral therapy (CBT) delivery for insomnia was
being tested in primary care using three methods
requiring different resources. Thus, the Organization
domain should have been rated separately for the
two interventions being compared to usual care.
One (Sleep Healthy Using the Internet) included a
self-guided Internet version of CBT and the second
(Brief Behavioral Treatment of Insomnia) involved a
provider who would likely need additional training.
Flexibility of Intervention Adherence
Each trial had a rating change on this domain, suggest-
ing that it may be harder to assess initially, in particular
when considering recipients who have consented to a
procedure but thereafter are not involved in adherence
issues with the intervention. This domain can benefit
from discussion to create consensus among trial de-
signers due to uncertainty in how much monitoring and
feedback is routine; a fully pragmatic design would
accept full flexibility in how the patient (recipient) inter-
acted with the intervention. Several of the trials illustrate
challenges with rating this domain:
 In the ENGAGES trial [30], testing if an
electroencephalography-guided protocol in elderly
patients undergoing major elective surgery decreases
the incidence of postoperative delirium, it could be
argued that this domain was not applicable as the
patients had given consent to the operation and
being part of the trial. The official guidance [9] in
the PRECIS-2 toolkit is that the domain should not
be rated, as follows, “In some trials, e.g., surgical trials
where patients are being operated on or intensive care
unit trials where patients are being given intravenously
administered drug therapy, this domain is not
applicable as there is no compliance issue after
consent has been given, so this score should be left
blank.”
Table 5 Principal investigator (PI) reflections on the PRECIS-2
tool
Rating scale Would have
been useful in
design phase (N)
Highlighted areas
important for trial
to achieve goals (N)
Strongly agree 2 1
Somewhat agree 3 2
Neither agree or disagree 0 1
Somewhat disagree 0 1
Strongly disagree 0 0
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 Similarly, in the PART trial [32] this domain is also
not applicable as there was no compliance from the
patient who either got ETI or SGA airway management
resuscitation for OHCA.
 For the PROOFCheck trial [33] the domain is also
not applicable as patients were not involved in
compliance; confusion may have occurred because
adherence for physicians (the interventionist) was
tested on use of checklists to determine which
patients required mechanical ventilation to prevent
severe acute respiratory failure (ARF). This domain
is relevant for the HUSH trial [31]. For patients in
the SHUTi arm of the trial adherence was encouraged
using automated emails only, whereas in the Brief
Behavioral Treatment of Insomnia (BBTI) arm the
provider reviews progress with the participant for
15–30 minutes each week for 3 weeks to adjust sleep/
wake times, which might be related to usual
encouragement from a doctor. Due to the different
ways of encouraging adherence, however, each of
these interventions may be rated differently by
trialists. Further clarification may be needed to assist
trialists to score this domain accurately. In the
REDAPS trial [34], however, with an intervention
to test out the default option for palliative care
consultation, the PI anticipated that the
intervention could be fully pragmatic “5” but had
marked down to “4” due to uncertainty
implementing into usual care.
Follow-up
Burden on the research team to collect the follow-up
data required to address the primary research question
is not assessed on the PRECIS-2 tool and was misapplied
to Follow-up in two instances. The only consideration
for this domain is how different is the intensity of meas-
urement and follow-up for patients/participants from
what is typical in usual care. The effort required to col-
lect follow-up data is also not a consideration under
Organization, which pertains to the resources required
to deliver the intervention, not the effort to measure
outcomes.
Conclusions
Use of the PRECIS-2 tool has provided an important
framework for the project team to organize observations
about critical elements underlying design decisions that
impact the position of the trial along the pragmatic-
explanatory continuum, and to communicate more ef-
fectively with their trial stakeholders about these ele-
ments. Prior to the Pragmatic Trials Collaborative
Project, two of the PIs were familiar with the earlier ver-
sion of the tool, and none had had extensive training or
experience applying it to trial design. The training
provided at each annual meeting was less extensive than
trainings intended to achieve inter-rater reliability; there-
fore, it is not unexpected that the rationales provided to
justify ratings revealed several common themes requir-
ing additional clarification. Continuing to refine our un-
derstanding, we believe, is critical for communicating
about decisions and for valid comparisons of design
characteristics and their consequences.
What we have learned from ongoing monitoring of
milestone achievement during the planning phase is that
these low-cost trials required sustained attention to a
range of underlying shifts in healthcare delivery and
health system operations. These scenarios can create
surprise challenges for investigators well into the prag-
matic clinical trial life span. Our conclusion that trial de-
sign decisions may be relatively stable, even for
pragmatic trials subject to real-world implementation
challenges, should be further explored in a larger set of
pragmatic trials. Furthermore, we did not explore trial
changes not reflected in the PRECIS domain structure,
discuss domains with no change in rating as they were
beyond the scope of our qualitative follow-up, or check
for false negatives wherein actual domain changes were
not captured.
Our Pragmatic Trials Collaborative Project is a timely
opportunity to understand the contexts in which com-
plex pragmatic trials are being conducted, and the inves-
tigators and NIH project officers have benefitted from
learning how each study team is striving to ensure that
they fulfill the intended purpose of the trial. Overall,
there has been a positive response to using PRECIS-2 to
guide conversations around trial design, and the project’s
focus on the use of the tool by this group of early
adopters has provided valuable feedback to inform fu-
ture trainings on the tool. In addition to evidence that
the tool is increasingly included in study protocols and
publications, the use of the tool in proposals indicates a
critical need for sponsors of pragmatic trials and mem-
bers of review panels—as well as future trial designer-
s—to be knowledgeable regarding how to rate and
interpret the PRECIS-2 ratings.
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